BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
2 Murakami K, Kumata H, Miyagi S, Kamei T, Sasano H. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma. Pathol Int 2021. [PMID: 34320691 DOI: 10.1111/pin.13149] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Tao L, Chen Y, Huang Y, Yin W, Yu G. SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation. J Clin Pathol 2020:jclinpath-2020-206903. [PMID: 33132215 DOI: 10.1136/jclinpath-2020-206903] [Reference Citation Analysis]
4 Polowczyk B, Kałużny M, Bolanowski M. Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects. Postepy Hig Med Dosw 2020;74:272-82. [DOI: 10.5604/01.3001.0014.3056] [Reference Citation Analysis]
5 Tao L, Chen Y, Shi X, Yu G, Yin W, Huang Y. Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma. Virchows Arch 2020;477:573-9. [PMID: 32328798 DOI: 10.1007/s00428-020-02815-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
7 Ulaner GA, Bodei L. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. Clin Nucl Med 2019;44:330-1. [PMID: 30688738 DOI: 10.1097/RLU.0000000000002467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tabacchi E, Campana D, Brighi N, Fanti S, Ambrosini V. 68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. Clin Nucl Med 2019;44:238-9. [DOI: 10.1097/rlu.0000000000002426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]